Land: Australien
Sprache: Englisch
Quelle: Department of Health (Therapeutic Goods Administration)
meloxicam, Quantity: 15 mg
Alphapharm Pty Ltd
Meloxicam
Tablet, uncoated
Excipient Ingredients: magnesium stearate; sodium citrate dihydrate; pregelatinised maize starch; maize starch; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica
Oral
30 Tablets, 10 tablets
(S4) Prescription Only Medicine
Symptomatic treatment of osteoarthritis and rheumatoid arthritis.
Visual Identification: Pale yellow coloured, circular 10mm, flat bevelled uncoated tablet, with central breakline on one side, plain on the other; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2007-05-15
MOXICAM TABLETS _meloxicam_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about MOXICAM. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking MOXICAM against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT MOXICAM IS USED FOR MOXICAM is used to treat the symptoms of osteoarthritis and rheumatoid arthritis. Both diseases mainly affect the joints causing pain and swelling. Although MOXICAM can relieve symptoms such as pain and inflammation, it will not cure your condition. MOXICAM belongs to a family of medicines called Non-Steroidal Anti- inflammatory Drugs (NSAIDs). These medicines work by relieving pain and inflammation. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. It is available only with a doctor's prescription. BEFORE YOU TAKE MOXICAM _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE MOXICAM IF YOU HAVE AN ALLERGY TO: • any medicine containing meloxicam • any of the other ingredients listed at the end of this leaflet • aspirin or any other NSAID medicine Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin DO NOT TAKE MOXICAM IF: • you are about to undergo coronary artery bypass graft surgery • you have a disease of the heart with shortness of breath and swelling of the feet or lips due to fluid build-up • you experience bleeding from the stomach, gut or any other bleeding • you have had a stroke resulting from a bleed in the brain or have a bleeding disorder • have a galact Lesen Sie das vollständige Dokument
AUSTRALIAN PRODUCT INFORMATION MOXICAM _meloxicam tablets _ 1 NAME OF THE MEDICINE Meloxicam 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each MOXICAM tablet consists of 7.5 mg or 15 mg of the active ingredient meloxicam. Excipient with known effect: lactose. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM MOXICAM meloxicam 7.5 mg tablets: Each tablet contains 7.5 mg of meloxicam as the active ingredient, presented as a yellow coloured, circular 7 mm, flat bevelled uncoated tablet, with central break line on one side, plain on the other. MOXICAM meloxicam 15 mg tablets: Each tablet contains 15 mg of meloxicam as the active ingredient, presented as a pale yellow coloured, circular 10 mm, flat bevelled uncoated tablet, with central break line on one side, plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MOXICAM tablets are indicated for the symptomatic treatment of osteoarthritis and rheumatoid arthritis. 4.2 DOSE AND METHOD OF ADMINISTRATION MOXICAM should be used at the lowest dose and for the shortest duration consistent with effective treatment. The maximum recommended daily dose of MOXICAM is 15 mg. A dose of 15 mg/day should not be exceeded. As a dose for children has not been established, use should be restricted to adults (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE – Paediatric Use). The dose of MOXICAM in patients with end-stage renal failure on haemodialysis should not exceed 7.5 mg/day (see Section 5.2 PHARMACOKINETIC PROPERTIES – Renal Impairment and Section 5.2 PHARMACOKINETIC PROPERTIES – Haemodialysis). No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 mL/min) nor in patients with mild to moderate hepatic impairment. In non-dialysed patients with severe renal impairment MOXICAM is contraindicated (see Section 4.3 CONTRAINDICATIONS). In patients with increased risks of adverse reactions, e.g. a history of gastrointestinal dis Lesen Sie das vollständige Dokument